A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Trametinib (Primary) ; Uprosertib (Primary)
- Indications Breast cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 05 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 05 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.